What are the signs and symptoms of trisomy 13 (Patau syndrome) in infants?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 26, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Trisomy 13 (Patau Syndrome): Signs and Symptoms

Trisomy 13 presents with a characteristic triad of craniofacial, cardiac, and limb abnormalities, including microphthalmia/anophthalmia, cleft lip and palate, polydactyly, and severe congenital heart defects, with most affected infants dying within the first year of life. 1, 2, 3

Craniofacial Features

The most recognizable facial abnormalities include:

  • Cleft lip and palate - present in the majority of cases and often bilateral 1, 2, 4
  • Microphthalmia or anophthalmia (small or absent eyes) - part of the classic clinical triad 2, 4
  • Microcephaly with sloping forehead - characteristic head shape abnormality 2
  • Low-set ears with abnormal ear structure 2
  • Short neck 2

These dysmorphic features are typically evident at birth and aid in clinical diagnosis even before chromosomal confirmation 1, 2.

Cardiac Abnormalities

Congenital heart defects occur in up to 80% of patients and are a major cause of early mortality:

  • Ventricular septal defect (VSD) - most common cardiac lesion 1
  • Atrial septal defect (ASD) 1
  • Patent ductus arteriosus (PDA) 1
  • Non-cyanotic heart defects are more common than cyanotic lesions 4

A pansystolic murmur at the left sternal border is frequently detected on initial examination 1. Cardiac complications are well-described and contribute significantly to the high mortality rate 3.

Limb and Skeletal Abnormalities

  • Polydactyly (extra fingers or toes) - part of the classic triad 2, 4
  • Congenital clubfoot 1
  • Orthopedic complications requiring monitoring 3

Central Nervous System Defects

  • Holoprosencephaly - though less frequent than historically reported, remains a serious finding 4
  • Neurological complications affecting quality of life 3
  • Severe intellectual disabilities in survivors 5

Abdominal and Genitourinary Abnormalities

  • Omphalocele (abdominal wall defect) - occurs less frequently than previously stated in literature 4
  • Polycystic kidney disease 4
  • Genitourinary complications requiring surveillance 3
  • Single umbilical artery - though less common than expected 4

Other Systemic Manifestations

  • Respiratory complications - significant contributor to morbidity 3
  • Otolaryngologic issues 3
  • Abdominal complications 3

Prognosis and Survival

  • Mortality rate of 85-90% within the first year of life, with most deaths occurring before 6 months 1, 3
  • Median survival of approximately 95 days in recent series 4
  • Only 5-10% survive beyond the first year, with mosaic or partial trisomy 13 having better prognosis than full trisomy 6
  • The longest documented survivor of non-mosaic trisomy 13 reached 84 months 4

Clinical Variability and Mosaicism

Important caveat: Variable expressivity exists even in non-mosaic cases, not solely related to chromosomal mosaicism 4. Patients with mosaic trisomy 13 demonstrate different clinical spectra and improved survival compared to full trisomy 5, 4. The severity of associated anomalies—particularly absence of holoprosencephaly, omphalocele, and severe renal disease—correlates with longer survival 4.

Prenatal Detection

  • Low hCG levels (approximately 0.62 multiples of median) on maternal serum screening, opposite to the elevated pattern seen in Down syndrome 7
  • Prenatal ultrasound may detect major structural anomalies, though certain serious defects occur less frequently than expected 4
  • Diagnostic confirmation requires chromosomal analysis via CVS or amniocentesis 8

References

Research

An infant with patau syndrome associated with congenital heart defects.

Annals of medicine and surgery (2012), 2022

Research

Surveillance guidelines for children with trisomy 13.

American journal of medical genetics. Part A, 2021

Research

Variable expressivity in Patau syndrome is not all related to trisomy 13 mosaicism.

American journal of medical genetics. Part A, 2007

Guideline

Management and Treatment Approach for Edward's Syndrome (Trisomy 18)

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Trisomy Screening and hCG Levels

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Related Questions

What is the treatment plan for a newborn with Patau syndrome?
What is the best approach for feeding an individual with Patau syndrome and cleft lip and palate using a long-handled spoon?
What is the diagnosis and treatment for Trisomy 13 (Patau syndrome)?
What are the chances of having a child with Trisomy 13 (Patau syndrome)?
What is the life expectancy for an individual with Trisomy 13 (Patau syndrome)?
What are the clinical presentations and patient profiles that should raise suspicion for cauda equina syndrome, particularly in those with a history of recent trauma, back pain, spinal surgery, spinal stenosis, herniated discs, or tumors?
What is the best approach for managing a patient with type 2 diabetes, insulin resistance, and hirsutism using dapagliflozin, vidagliptin, and metformin?
What studies demonstrate the advantage of piperacillin-tazobactam (antibiotic) in patients with high-risk febrile neutropenia, particularly those with hematological malignancies or undergoing chemotherapy?
What to do for a patient on citalopram (escitalopram) experiencing a significant worsening of symptoms in week 7?
I stopped consuming caffeine 3 weeks ago and am experiencing persistent headaches and high-pitched tinnitus, could these symptoms be related to my caffeine withdrawal, given my history of mixed headaches and tinnitus triggered by mood disorders and stress overload?
What is the approach to diagnosis and management of Henoch-Schonlein purpura (HSP) in a pediatric patient, likely between 3-10 years old, presenting with suspected HSP?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.